

RECEIVED

JUN 13 2001

TECH CENTER 1600/2900

#3  
1645

PATENT

Docket No. 399632000325

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231, on June 7, 2001.

*U. Britva*  
Irina Britva

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Ralph T. KUBO et al.

Serial No.: 09/665,510

Filing Date: September 19, 2000

For: HLA BINDING PEPTIDES AND THEIR  
USES

Examiner: To be Assigned

Group Art Unit: 1645

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents, except Nos. 3-5, 7, 8, 11-16, 30, 31 and 46, were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 08/347,610, filed December 01, 1994, and 08/159,339, filed November 29, 1993, now U.S. Patent 6,037,135, and, accordingly, copies are not included herewith. Copies of the above-listed documents are included. This protocol conforms with 37 C.F.R. § 1.98(d) and M.P.E.P.

609(A)(2). The Examiner is requested to make these documents of record in the application.

The documents Nos. 8, 11-16, 30, 31 and 46 listed on the attached Form PTO-1449 were cited in a Search Report (copy attached) directed to a counterpart international or foreign application.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of \* is enclosed.
  - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee. Accordingly, a Petition requesting consideration of the Information Disclosure Statement, an authorization to charge our deposit account, and a Certification under 37 C.F.R. § 1.97(e) are provided herein.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is to the best of my knowledge and is not to be construed as a representation

RECEIVED

JUN 13 2001


TECH CENTER 1600/2900

that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.


In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 399632000325. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: June 7, 2001

Respectfully submitted,

By:   
Bruce Grant  
Registration No. 47,608

Morrison & Foerster LLP  
3811 Valley Centre Drive  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-7962  
Facsimile: (858) 720-5125

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> (Use several sheets if necessary) 	Docket Number 399632000325	Application Number 09/665,510
	Applicant Ralph T. KUBO et al.	
	Filing Date September 19, 2000	Group Art Unit 1645
	Mailing Date: June 7, 2001	

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	04/1993	5,200,320	Sette et al.	435	7.24	
	2.	08/1994	5,342,774	Boon et al.	435	240.2	
	3.	04/1995	5,405,940	Boon et al.	530	328	
	4.	10/1995	5,462,871	Boon-Falleur et al.	435	240.2	
	5.	12/1997	5,695,994	Boon-Falleur et al.	435	325	
	6.	05/1998	5,750,395	Fikes et al.	435	325	
	7.	03/2000	6,034,214	Boon et al.	530	328	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES	NO
	8.	06/1987	EP0226513A ✓	EP				
	9.	12/1989	EP0346022A1	EP				
	10.	02/1992	WO 92/02543	PCT				
	11.	08/1992	WO 92/12996 ✓	PCT				
	12.	11/1992	WO 92/21033 ✓	PCT				
	13.	03/1993	WO 93/03753 ✓	PCT				
	14.	03/1993	EP 0534615A ✓	EP				
	15.	09/1993	WO 93/17095 ✓	PCT				
	16.	11/1993	WO 93/22338	PCT				
	17.	03/1994	WO 94/05304	PCT				
	18.	08/1994	WO 94/11738	PCT				

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	19.	Bjorkman, et al. (1987). <i>Nature</i> 329:506.

EXAMINER: (examiner)

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 399632000325

Application Number 09/665,510

Applicant

Ralph T. KUBO et al.


Filing Date September 19, 2000

Group Art Unit 1645

Mailing Date: June 7, 2001

# INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)



- |     |   |
|-----|---|
| 20. | Bruss, V. (1997). <i>J Virology</i> 71(12):9350-9357.                     |
| 21. | Buus, et al. (1988). <i>Science</i> 242:1045-1047.                        |
| 22. | Carreno, B et al. (1990). <i>Proc Natl Acad Sci</i> 87:3420-3424.         |
| 23. | Celis, E. et al. (1994). <i>Proc Natl Acad Sci</i> 91:2105-2109.          |
| 24. | Celis, E. et al. (1994). <i>Mol Immunol</i> 31:1423-1430.                 |
| 25. | De Bruijn, M. et al. (1991). <i>Eur J Immunol</i> 21:2963-2970.           |
| 26. | DiBrino, M. et al. (1993). <i>Proc Natl Acad Sci</i> 90:1508-1512.        |
| 27. | DiBrino, M. et al. (1993). <i>J Immunol</i> 151(11):5930-5935.            |
| 28. | Ding, M. et al. (1994). <i>Biochem Biophys Res Commun</i> 202(1):549-555. |
| 29. | Engelhard, V. et al. (1994). <i>Curr Opin Immunol</i> 6:13-23.            |
| 30. | Falk, K. et al. (1991). <i>J Exp Med</i> 174:425-434.                     |
| 31. | Falk, K. et al. (1991). <i>Nature</i> 351:290-296.                        |
| 32. | Foon. (1989). <i>Cancer Res</i> 49:1621-1639.                             |
| 33. | Gaugler, B. et al. (1994). <i>J Exp Med</i> 179(3):921-930.               |
| 34. | Guo, et al. (1994). <i>Nature</i> 30:364-366.                             |
| 35. | Hayashi, et al. (1992). <i>J Immunol</i> 149:1223-1229.                   |
| 36. | Henderson, R. (1992). <i>Science</i> 255:1264-1266.                       |
| 37. | Hunt, D. et al. (1992). <i>Science</i> 255:1261-1263.                     |
| 38. | Jardetzky, T. et al. (1991). <i>Nature</i> 353:326-329.                   |
| 39. | Jiang, et al. (1992). <i>Science</i> 256:1213-1215.                       |
| 40. | Kannagi, M. et al. (1992). <i>J Virology</i> 66(5):2928-2933.             |
| 41. | Karin, et al. (1994). <i>J Exp Med</i> 180:2227-2237.                     |
| 42. | Knuth, et al. (1991). <i>Curr Opin Immunol</i> 3:659-664.                 |
| 43. | Koh, et al. (1992). <i>Science</i> 256:1210-1213.                         |
| 44. | Krieger, et al. (1991). <i>J Immunol</i> 146:2331-2340.                   |
| 45. | Maryanski, et al. (1990). <i>Cell</i> 60:63-72.                           |
| 46. | Melief, C. et al. (1992). <i>Cancer Surveys</i> 13:81-99.                 |
| 47. | Miller, et al. (1992). <i>Proc Natl Acad Sci</i> 89:421-425.              |
| 48. | Morrison, J. et al. (1992). <i>Eur J Immunol</i> 22:903-907.              |
| 49. | Oakes, M. et al. (1994). <i>Cancer Res</i> 54:1627-1629.                  |
| 50. | Ochoa-garay, et al. (1997). <i>Mol Immunol</i> 34:273-281.                |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 399632000325

Application Number 09/665,510

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Ralph T. KUBO et al.

Filing Date September 19, 2000

Group Art Unit 1645

Mailing Date: June 7, 2001

- |     |  |
|-----|--|
| 51. | Pamer, E. et al. (1991). <i>Nature</i> 353:852-855.  |
| 52. | Parker, K. et al. (1992). <i>J Biol Chem</i> 267(8):5451-5459.   |
| 53. | Parker, et al. (1992). <i>J Immunol</i> 149: 1222-1225.  |
| 54. | Paul, W. (ed.), <i>Fundamental Immunology</i> 3 <sup>rd</sup> ed., pp.976-978 (1993), Raven Press, NY.   |
| 55. | Preisler-Adams, S. et al. (1993). <i>Nucleic Acids Res</i> 21(9):2258.   |
| 56. | Rammensee, H. et al. (1993). <i>Annu Rev Immunol</i> 11:213-244.   |
| 57. | Rammensee, H. et al. (1995). <i>Immunogenet</i> 41:178-228.  |
| 58. | Robbins. <i>Pathologic Basis of Disease</i> 4 <sup>th</sup> ed. (R.S. Cotran et al., ed.), pp.296-299 (1989), W.B. Saunders Co., Philadelphia. |
| 59. | Romero, et al. (1991). <i>J Exp Med</i> 174:603-612.   |
| 60. | Rotzschke, O. et al. (1990). <i>Science</i> 249:283-287.   |
| 61. | Rotzschke, O. et al. (1990). <i>Nature</i> 348:252-254.  |
| 62. | Rotzschke, O. et al. (1991). <i>Immunology Today</i> 12(12):447-455.   |
| 63. | Rotzschke, O. et al. (1992). <i>Eur J Immunol</i> 22:2453-2456.  |
| 64. | Sette, A. et al. (1989). <i>Proc Natl Acad Sci</i> 86:3296-3300.   |
| 65. | Sette, A. et al. (1991). <i>J Immunol</i> 147:3893-3900.   |
| 66. | Shimojo, N. et al. (1989). <i>J Immunol</i> 143(9):2939-2947.  |
| 67. | Slingluff, et al. (1993). <i>J Immunol</i> 150:2955-2960.  |
| 68. | Storkus, et al. (1993). <i>J Immunol</i> 151:3719-3727.  |
| 69. | Traversari, C. et al. (1992). <i>J Exp Med</i> 176:1453-1457.  |
| 70. | Urban, J. et al. (1989). <i>Cell</i> 59:257-271.   |
| 71. | Van der Bruggen, et al. (1991). <i>Science</i> 254:1643-1647.  |
| 72. | Viret, et al. (1993). <i>Eur J Immunol</i> 23:141-146.   |
| 73. | Weynants, P. et al. (1994). <i>Int J Cancer</i> 56:826-829.  |
| 74. | Wraith, D. (1989). <i>Cell</i> 259:247-255.  |
| 75. | Zakut, R. et al. (1993) <i>Cancer Res</i> 53:5-8.  |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.